Natera, Inc. (NTRA) shareholders
Close on Nov 17, 2026Market cap $41.44BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (10.50%) | 15,131,245 | 10.50% | 13G (passive) amendment | Oct 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (9.50%) | 13,659,508 | 9.50% | 13G (passive) | Sep 30, 2026 |
| JPMorgan Chase & Co. | 12,825,640 | 9.10% | 13G (passive) amendment | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 9,021,825 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 7,565,936 | 5.60% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 7,205,939 | 5.08% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NTRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 12,865,346 | 8.93% | $3.51B | −521,321 | 0.19% |
| BlackRock, Inc. | 10,914,608 | 7.57% | $2.96B | +237,270 | 0.04% |
| Price T Rowe Associates Inc /Md/ | 9,021,895 | 6.26% | $2.45B | −3,162,981 | 0.25% |
| Vanguard Capital Management LLC | 6,228,216 | 4.32% | $1.69B | +219,720 | 0.04% |
| Vanguard Portfolio Management LLC | 5,782,640 | 4.01% | $1.57B | +137,945 | 0.07% |
| FMR LLC | 5,451,396 | 3.78% | $1.48B | +2,897,142 | 0.06% |
| Wellington Management Group Llp | 4,040,738 | 2.80% | $1.10B | −727,855 | 0.19% |
| State Street Corp | 3,655,618 | 2.54% | $992.32M | +238,146 | 0.03% |
| Duquesne Family Office LLC | 3,186,306 | 2.21% | $864.92M | +122,700 | 16.60% |
| Geode Capital Management, LLC | 2,750,013 | 1.91% | $744.57M | −25,915 | 0.04% |
| Franklin Resources Inc | 2,725,903 | 1.89% | $739.95M | +240,578 | 0.16% |
| Castle Hook Partners LP | 2,596,276 | 1.80% | $704.76M | +66,466 | 3.23% |
| Coatue Management LLC | 2,505,090 | 1.74% | $680.01M | −36,752 | 1.40% |
| Aqr Capital Management LLC | 2,344,570 | 1.63% | $628.09M | +70,579 | 0.22% |
| Farallon Capital Management LLC | 2,218,366 | 1.54% | $602.18M | −989,000 | 2.78% |
| Massachusetts Financial Services Co /Ma/ | 1,971,391 | 1.37% | $535.08M | −68,715 | 0.17% |
| Norges Bank | 1,828,122 | 1.27% | $496.24M | New | 0.05% |
| Fred Alger Management, LLC | 1,778,009 | 1.23% | $482.64M | +21,537 | 1.61% |
| Goldman Sachs Group Inc | 1,720,152 | 1.19% | $466.94M | +952,921 | 0.04% |
| Sofinnova Investments, Inc. | 1,550,280 | 1.08% | $420.82M | – | 21.76% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 846 | 137M | 95.2% | 157 / 356 | 242 / 66 | 15M | 12M |
| Q1 2026 | 766 | 134M | 93.2% | 98 / 301 | 265 / 106 | 23M | 9M |
| Q4 2025 | 785 | 133M | 92.5% | 185 / 277 | 241 / 63 | 16M | 24M |
| Q3 2025 | 686 | 142M | 98.5% | 111 / 269 | 230 / 65 | 22M | 11M |
| Q2 2025 | 648 | 132M | 91.5% | 110 / 272 | 197 / 55 | 16M | 14M |
| Q1 2025 | 597 | 130M | 90.4% | 116 / 238 | 192 / 103 | 18M | 12M |
| Q4 2024 | 596 | 125M | 86.7% | 146 / 185 | 211 / 37 | 15M | 16M |
| Q3 2024 | 495 | 126M | 87.6% | 68 / 180 | 195 / 42 | 21M | 17M |
| Q2 2024 | 475 | 129M | 89.4% | 96 / 184 | 147 / 29 | 15M | 16M |
| Q1 2024 | 411 | 131M | 90.7% | 96 / 145 | 135 / 34 | 20M | 13M |
| Q4 2023 | 351 | 124M | 86.0% | 67 / 129 | 127 / 32 | 23M | 14M |
| Q3 2023 | 319 | 115M | 79.6% | 43 / 113 | 120 / 38 | 14M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
686 funds held NTRA in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NTRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| JPMorgan Large Cap Growth Fund | 5,550,940 | 3.85% | $1.51B | 1.24% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,320,351 | 3.00% | $1.17B | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,119,416 | 2.16% | $846.77M | 0.45% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,799,359 | 1.25% | $488.44M | 1.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,642,271 | 1.14% | $445.79M | 0.46% | Jun 30, 2026 |
| Fidelity Contrafund | 1,617,222 | 1.12% | $438.99M | 0.24% | Jun 30, 2026 |
| Franklin Dynatech Fund | 1,450,000 | 1.01% | $393.60M | 1.30% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 1,345,572 | 0.93% | $300.56M | 2.18% | May 31, 2026 |
| Growth Fund of America | 988,724 | 0.69% | $220.85M | 0.06% | May 31, 2026 |
| iShares Biotechnology ETF | 967,683 | 0.67% | $262.68M | 2.89% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 817,775 | 0.57% | $221.99M | 1.51% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 805,893 | 0.56% | $218.76M | 1.01% | Jun 30, 2026 |
| T. Rowe Price Large-Cap Growth Fund | 800,499 | 0.56% | $217.30M | 1.06% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 783,620 | 0.54% | $175.04M | 0.37% | May 31, 2026 |
| JPMorgan Mid Cap Growth Fund | 781,556 | 0.54% | $212.15M | 1.60% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN, Director | 2,116,928 | 1.47% | Nov 4, 2026 |
| Steven Leonard Chapman | CEO AND PRESIDENT, Director | 87,431 | 0.06% | Nov 4, 2026 |
| Daniel Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 167,880 | 0.12% | Nov 4, 2026 |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 195,276 | 0.14% | Nov 4, 2026 |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 101,323 | 0.07% | Nov 4, 2026 |
| Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | 45,779 | 0.03% | Nov 4, 2026 |
| Jonathan Sheena | Director | 229,462 | 0.16% | Nov 13, 2026 |
| Rowan E. Chapman | Director | 4,663 | 0.00% | Jul 17, 2026 |
| Eric H. Rubin | Director | 2,204 | 0.00% | Jun 30, 2026 |
| Roelof Botha | Director | 1,080,663 | 0.75% | Jun 30, 2026 |
| Roy D. Baynes | Director | 20,083 | 0.01% | Jun 30, 2026 |
| Thomas J. Lynch Jr. | Director | 1,905 | 0.00% | Jun 30, 2026 |
| Herm Rosenman | Director | 5,821 | 0.00% | Jun 30, 2026 |
| Gail Boxer Marcus | Director | 7,852 | 0.01% | Jun 30, 2026 |
| Monica Bertagnolli | Director | 6,945 | 0.00% | Jun 30, 2026 |
| Brinkley Ruth Williams | Director | 5,475 | 0.00% | Apr 28, 2026 |
| James Healy | Director | 1,596,540 | 1.11% | Apr 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −40 | $324.76 | $12.99K | 7,500 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −80 | $322.88 | $25.83K | 7,540 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −120 | $320.07 | $38.41K | 7,620 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −240 | $319.22 | $76.61K | 7,740 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −182 | $317.96 | $57.87K | 7,980 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −48 | $317.33 | $15.23K | 8,162 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −40 | $315.28 | $12.61K | 8,210 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −40 | $323.06 | $12.92K | 7,500 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −40 | $322.00 | $12.88K | 7,540 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −160 | $320.02 | $51.20K | 7,580 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −240 | $319.77 | $76.75K | 7,740 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −145 | $317.87 | $46.09K | 7,980 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −85 | $316.93 | $26.94K | 8,125 |
| Jonathan Sheena Director | Nov 11, 2026 | Sale(10b5-1 plan) | −40 | $315.26 | $12.61K | 8,210 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −45 | $325.05 | $14.63K | 214,462 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −40 | $323.86 | $12.95K | 214,507 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −16 | $321.85 | $5.15K | 214,547 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −51 | $321.12 | $16.38K | 214,563 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −131 | $320.07 | $41.93K | 214,614 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −105 | $319.30 | $33.53K | 214,745 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −56 | $318.17 | $17.82K | 214,850 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −1,838 | $316.87 | $582.40K | 214,906 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −169 | $315.48 | $53.32K | 216,744 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −108 | $314.71 | $33.99K | 216,913 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −74 | $313.32 | $23.19K | 217,021 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −106 | $312.20 | $33.09K | 217,095 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −100 | $311.31 | $31.13K | 217,201 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −110 | $310.17 | $34.12K | 217,301 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −64 | $309.08 | $19.78K | 217,411 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −50 | $308.20 | $15.41K | 217,475 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −21 | $306.46 | $6.44K | 217,525 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −51 | $305.75 | $15.59K | 217,546 |
| Jonathan Sheena Director | Nov 6, 2026 | Sale(10b5-1 plan) | −15 | $304.57 | $4.57K | 217,597 |
| Michael Burkes Brophy CHIEF FINANCIAL OFFICER | Nov 3, 2026 | Sale(10b5-1 plan) | −470 | $391.49 | $184.00K | 45,779 |
| John Fesko PRESIDENT, CHIEF BUS. OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −295 | $400.29 | $118.09K | 195,276 |
| John Fesko PRESIDENT, CHIEF BUS. OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −7 | $388.20 | $2.72K | 195,571 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −240 | $416.45 | $99.95K | 101,323 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −760 | $415.52 | $315.79K | 101,563 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −80 | $414.16 | $33.13K | 102,323 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −120 | $412.88 | $49.55K | 102,403 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −120 | $411.73 | $49.41K | 102,523 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −120 | $410.71 | $49.29K | 102,643 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −520 | $409.46 | $212.92K | 102,763 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −408 | $408.08 | $166.50K | 103,283 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −432 | $406.94 | $175.80K | 103,691 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −200 | $405.26 | $81.05K | 104,123 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −410 | $400.29 | $164.12K | 104,323 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Nov 2, 2026 | Sale(10b5-1 plan) | −9 | $388.20 | $3.49K | 104,733 |
| Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −334 | $400.29 | $133.70K | 167,880 |
| Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −7 | $388.20 | $2.72K | 168,214 |
| Steven Leonard Chapman CEO AND PRESIDENT, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −2,866 | $415.64 | $1.19M | 87,431 |
| Steven Leonard Chapman CEO AND PRESIDENT, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −914 | $400.29 | $365.87K | 90,297 |
| Steven Leonard Chapman CEO AND PRESIDENT, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −21 | $387.90 | $8.15K | 91,211 |
| Michael Burkes Brophy CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −317 | $400.29 | $126.89K | 46,249 |
| Michael Burkes Brophy CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −8 | $388.03 | $3.10K | 46,566 |
| Jonathan Sheena Director | Nov 2, 2026 | Sale(10b5-1 plan) | −109 | $400.29 | $43.63K | 217,574 |
| Jonathan Sheena Director | Nov 2, 2026 | Sale(10b5-1 plan) | −3 | $388.20 | $1.16K | 217,683 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −731 | $400.29 | $292.62K | 2,116,928 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −17 | $388.20 | $6.60K | 2,117,659 |
| Michael Burkes Brophy CHIEF FINANCIAL OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −1,906 | $425.55 | $811.10K | 46,574 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Natera's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,972 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael Burkes Brophy Officer | Nov 3, 2026 | 470 | $178.09K | Nov 3, 2026 | Restricted Stock Units |
| Steven Leonard Chapman Officer, Director | Nov 2, 2026 | 2,866 | $1.19M | Nov 2, 2026 | Restricted Stock |
| Jonathan Sheena DIRECTOR | Nov 2, 2026 | 108 | $44.74K | Nov 2, 2026 | Restricted Stock Units |
| Matthew Rabinowitz DIRECTOR | Nov 2, 2026 | 722 | $299.12K | Nov 2, 2026 | Restricted Stock Units |
| Daniel Rabinowitz OFFICER | Nov 2, 2026 | 330 | $136.72K | Nov 2, 2026 | Restricted Stock Units |
| Solomon Moshkevich OFFICER | Nov 2, 2026 | 405 | $167.79K | Nov 2, 2026 | Restricted Stock Units |
| John Fesko OFFICER | Nov 2, 2026 | 291 | $120.56K | Nov 2, 2026 | Restricted Stock Units |
| Steven Leonard Chapman OFFICER, DIRECTOR | Nov 2, 2026 | 903 | $374.11K | Nov 2, 2026 | Restricted Stock Units |
| Michael Burkes Brophy OFFICER | Nov 2, 2026 | 313 | $129.68K | Nov 2, 2026 | Restricted Stock Units |
| Solomon Moshkevich Officer | Nov 2, 2026 | 3,000 | $1.23M | Nov 2, 2026 | Restricted Stock |
| Michael Burkes Brophy Officer | Oct 30, 2026 | 1,906 | $831.02K | Oct 30, 2026 | Restricted Stock Units |
| Michael Burkes Brophy Officer | Oct 28, 2026 | 1,178 | $483.95K | Oct 28, 2026 | Restricted Stock Units |
| Jonathan Sheena DIRECTOR | Oct 28, 2026 | 191 | $78.47K | Oct 28, 2026 | Restricted Stock Units |
| Daniel Rabinowitz OFFICER | Oct 28, 2026 | 988 | $405.89K | Oct 28, 2026 | Restricted Stock Units |
| Solomon Moshkevich OFFICER | Oct 28, 2026 | 1,185 | $486.82K | Oct 28, 2026 | Restricted Stock Units |
Congress trades
6 trades in Natera reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Josh Gottheimer NJ05 · joint account | Bought | Sep 22, 2025 | $1K–15K | Oct 15, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Aug 22, 2025 | $1K–15K | Sep 5, 2025 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Jul 22, 2025 | $1K–15K | Aug 11, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Nov 20, 2024 | $1K–15K | Dec 5, 2024 |
| Daniel Goldman NY10 | Sold (part) | Apr 10, 2023 | $1K–15K | May 19, 2023 |
| Daniel Goldman NY10 | Bought | Mar 6, 2023 | $1K–15K | Apr 17, 2023 |
See a number that looks wrong?